Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Genpact Limited (NYSE: G) SEC filings, including current reports, registration statements, and other disclosures filed with the U.S. Securities and Exchange Commission. Genpact describes itself as an agentic and advanced technology solutions company, and its filings offer detailed insight into how it applies process intelligence and artificial intelligence within its business, as well as how it structures its capital and governance.
Investors can review Form 8-K filings for information on material events such as quarterly financial results, leadership changes, board appointments, and financing transactions. For example, recent 8-Ks discuss third quarter 2025 financial results, appointments of directors and senior officers, and the completion of a public offering of 4.950% Senior Notes due 2030 by Genpact UK Finco plc and Genpact USA, Inc., guaranteed by Genpact and Genpact Luxembourg.
Genpact also uses shelf registration statements and prospectus supplements on Form S-3 to register securities offerings, as reflected in the documentation supporting its 2030 senior notes. Credit agreement guarantees and supplemental indentures are described in exhibits to these filings, outlining covenants, guarantees, and change-of-control provisions relevant to Genpact’s debt structure.
On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key terms in 10-K and 10-Q reports, and surface notable items from Form 4 insider transaction reports where applicable. Real-time updates from EDGAR ensure that new Genpact filings appear promptly, allowing users to monitor financial performance, capital markets activity, and corporate governance developments through the company’s official regulatory disclosures.
Genpact LTD executive Piyush Mehta reported a routine tax-related share withholding. On 01/10/2026, 12,317 common shares were withheld at $48.24 per share to cover taxes due upon the vesting of restricted share units granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan, in a transaction exempt under Rule 16b-3.
After this transaction, Mehta directly beneficially owned 122,700 Genpact common shares. The filing also notes participation in the Genpact Employee Stock Purchase Plan, including 137 shares acquired since a prior Form 4, with a current total of 10,359 shares held under the ESPP.
Genpact Ltd’s Chief Financial Officer Michael Hal Weiner reported a routine tax-related share transaction. On January 10, 2026, 12,029 common shares were withheld at $48.24 per share to cover taxes due upon the vesting of restricted share units granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan, a transaction noted as exempt under Rule 16b-3. Following this withholding, Weiner beneficially owns 136,075 common shares directly. This total includes shares accumulated through the Genpact Employee Stock Purchase Plan, where he currently holds 1,436 shares, including 78 shares acquired since his prior Form 4 filed on November 17, 2025.
HEATHER D WHITE has filed a Form 144 notice to sell 10,740 shares of common stock of issuer G through Morgan Stanley Smith Barney LLC on or about 01/13/2026 on the NYSE. The planned sale has an aggregate market value of 500,964.08, compared with 172,414,423 shares of the same class reported as outstanding. The shares to be sold were acquired as restricted stock from the issuer on 01/10/2026.
Over the prior three months, the same seller reported three sales of common stock, totaling 45,703, 4,351, and 1,039 shares, for gross proceeds of 2,090,455.22, 199,014.74, and 45,731.59, respectively. By signing the notice, the seller represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or prospective operations.
A holder of common shares of the issuer associated with symbol G has filed a Form 144 notice to sell 15,088 common shares through Morgan Stanley Smith Barney LLC on the NYSE. The planned sale has an indicated aggregate market value of $703,788.81, with 172,414,423 common shares reported as outstanding and an approximate sale date of 01/13/2026.
The shares to be sold were acquired as restricted stock from the issuer on 01/10/2026, with the same date noted for payment and the nature of payment listed as not applicable. Over the past three months, the same seller, Sameer Dewan, sold 26,531 common shares for gross proceeds of $1,185,999.38, which is disclosed alongside the new planned sale.
A holder of common stock of G has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 16,016 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 01/13/2026. The aggregate market value of the shares listed for sale is $747,122.38, compared with 172,414,423 shares outstanding of the same class.
The shares to be sold were acquired as restricted stock from the issuer on 01/10/2026, with the consideration described as not applicable. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Genpact Limited reported that its SVP and Chief Legal Officer, Sydney Schaub, received an award of 63,357 common shares in the form of unvested restricted share units on 01/06/2026 at a grant price of $0 per share. Each RSU represents the right to receive one Genpact common share upon vesting. One-third of the shares underlying this RSU award will vest on each of December 8, 2026, December 8, 2027 and December 8, 2028, as long as Schaub continues in service through each vesting date. Following this grant, Schaub beneficially owned 63,357 common shares directly.
Genpact Limited reported an insider equity award to its President and CEO, who is also a director. On December 17, 2025, the executive received 125,130 restricted share units (RSUs) of Genpact common shares at a price of $0 per share, granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU converts into one common share when it vests.
One-third of the shares underlying this RSU award will vest on each of December 17, 2026, December 17, 2027 and December 17, 2028, contingent on the executive’s continued service through each vesting date. After this transaction, the executive beneficially owns 420,376 Genpact common shares directly.
Genpact LTD disclosed an insider ownership report for one of its senior executives. The filing relates to Sydney Schaub, who serves as SVP and Chief Legal Officer, with an event date of 12/08/2025.
According to the filing, no Genpact securities are beneficially owned, as noted in the explanation of responses. The form is filed for a single reporting person and is signed by Thomas D. Scholtes as attorney-in-fact for Sydney Schaub under a referenced power of attorney (Exhibit 24.1).
Genpact Limited announced that its subsidiaries Genpact UK Finco plc and Genpact USA, Inc. completed a public Notes Offering of $350 million aggregate principal amount of 4.950% Senior Notes due 2030. The notes are senior unsecured obligations of the co-issuers and are guaranteed on a senior unsecured basis by Genpact Limited and Genpact Luxembourg S.à r.l. The notes bear interest at 4.950% per year, payable semi-annually on May 18 and November 18, starting May 18, 2026, and mature on November 18, 2030.
Genpact intends to use the net proceeds for general corporate purposes, which may include repaying or redeeming its existing 1.750% senior notes due 2026. The new notes include customary covenants and a change of control repurchase right at 101% of principal plus accrued interest. Genpact UK also agreed to fully and unconditionally guarantee the 2026 and 6.000% 2029 notes and became a guarantor under the company’s second amended and restated credit agreement, further aligning guarantees across its debt structure.
Genpact Ltd (G) reported that its Chief Financial Officer filed a Form 4 disclosing an open-market sale of company stock. On 11/14/2025, the CFO sold 13,365 common shares of Genpact at a weighted average price of $44.84 per share, with individual sale prices ranging from $44.81 to $44.89. Following this transaction, the reporting person beneficially owns 148,026 Genpact common shares. This total includes 1,358 shares held under the Genpact Employee Stock Purchase Plan, of which 169 shares were acquired under the plan since a prior report filed on March 13, 2025.